Good day, ladies and gentlemen, and Welcome to Inari Medical, Inc. Third quarter 2021 Earnings Conference Call. At this time, all participant lines are in a listen-only mode. Later, we'll conduct a question-and-answer session and instructions will be given at that time. To ask a question, you will need to press star then one on your telephone. As a reminder, this call is being recorded. If anyone should require operator assistance, please press star then 0. I would now like to hand the conference over to your host today, Caroline Corner of Westwicke. Please go ahead. Thank you, operator. Welcome to Inari's Third Quarter 2021 Earnings Call. Joining me on today's call are Bill Hoffman, President and Chief Executive Officer, and Mitch Hill, Chief Financial Officer. This call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the markets in which Inari operates, trends and expectations for Inari's products and technology, trends and demands for Inari's products, Inari's expected financial performance, expenses and position in the market, and the impact of COVID-19 on Inari's operations and Inari's customers' operations. These statements are neither promises nor guarantees and involve known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from any results, performance or achievements expressed or implied by the forward-looking statements. Please review Inari's most recent filings with the SEC, particularly the risk factors described in Inari's annual report on Form 10-K and in Inari's quarterly report on Form 10-Q for the third quarter ended September 30, 2021 for additional information. Any forward-looking statements provided during this call, including projections for future performance, are based on management's expectations as of today. Inari undertakes no obligation to update these statements except as required by applicable law. Inari's press release with the third quarter 2021 results is available on Inari's website, www.inarimedical.com, under the Investors section, and includes additional details about Inari's financial results. Inari's website also has the latest SEC filings, which you are encouraged to review. A recording of today's call will be available on Inari's website by 5:05 P.M. Pacific Time today. Now I'd like to turn the call over to Bill for his comments and third quarter 2021 business highlights. Thank you, Caroline, and thank you everyone for joining us today. Our third quarter was productive and successful, and we again treated a record number of patients. Our execution remains crisp in all parts of our business, and we continue to make significant progress on all five of our growth drivers. We are excited to share additional detail about our performance, but we would like to begin, as usual, with a patient story that might remind you of the wonderful impact our products and our people have on the lives of our patients. A couple of months ago, at the peak of the most recent COVID surge in Houston, Texas, one of the hardest hit regions in the U.S., a young woman presented to the emergency department of a hospital near her home with shortness of breath and chest pain. She was three weeks postpartum and so fatigued that she was struggling to take care of her newborn. Imaging tests revealed large blood clots in both her left and right lungs. The hospital was full of COVID patients and had no ICU beds available. Thrombolytic therapy, which necessitates an ICU stay, was the only treatment available, so this patient could not be treated. She was sent home that evening on oral anticoagulants, which reduce the risk of developing new clots but do not eliminate existing clots. The following day, with worsening symptoms and now unable to climb the stairs to tend for her crying baby, she called an ambulance, which took her to a different hospital. This hospital was equally overwhelmed with COVID patients and also had no ICU beds. This hospital had been using Inari devices for more than a year. Inari procedures do not require an ICU stay. Within just one hour of her arrival at the hospital, the physician had already removed the entire clot burden from both lungs using FlowTriever. Her symptoms resolved, her vital signs returned to normal, and she was moved to a regular hospital bed. In less than two days, she was home with her new baby. The profound effect on the life of this young mom is perhaps as obvious as it is beautiful, as is the change in the trajectory of the life of her baby. Although we learn of these patient outcomes and such outcomes and stories like this on an almost daily basis now, we remain mindful of their impact. We are thankful always for the opportunity to pursue this mission and our life's work. This story highlights just some of the reasons we continue to perform well in perhaps the most challenging operating environment of our lifetime. Inari procedures are safe, effective, fast, easy to perform, and require limited hospital resource. This is even more important in the current environment's significant shortages of staff, hospital beds and ICU beds. While COVID might continue to wax and wane, we believe that these resource limitations will persist into 2022. We believe our clinical and economic value proposition will continue to resonate through and well beyond the pandemic. One final postscript to this story. The physician who treated this patient shared the story with his peers and the administrators of the hospital first visited by this patient, and I'm happy to report they now are also using FlowTriever. I'd like now to turn our attention to our Q3 financial performance. Our revenue in Q3 was $72.9 million, up $34.2 million or 88% from the same quarter last year and up $9.4 million or 15% from Q2. Procedure growth was robust. Our physician customers performed approximately 6,700 procedures, including a modest number of cases from Europe. This procedure count is up from 5,900 or about 14% from Q2. We believe that COVID-associated procedures represented about 11% of the total volume of procedures, similar to the 12% of COVID-associated procedures we saw during the previous surge in Q1. Growth in those patients whose VTE is not associated with COVID was 8%. Assuming we see the ongoing abatement of COVID, we anticipate a tempering of the number of COVID-associated procedures during Q4. Regardless, we expect to drive robust procedure growth within our core TAM as we have demonstrated throughout this pandemic. Despite the continued questions about COVID and its impact on our business, we have made steady progress on all of our growth drivers, and we have grown in every single quarter since the pandemic began in Q1 of 2020. In fact, during the pandemic, we've completed over 30,000 procedures and nearly tripled our quarterly production of both cases and revenue. We added 500 new customer accounts, hired and trained over 100 new sales professionals, developed our VTE Excellence Program to drive deeper adoption, created and executed our Clot Warrior Academy online training and education platform, which has now reached over 4,500 customers. We enrolled over 800 patients into our FLASH and Clot registries, published over 100 studies in peer-reviewed journals, initiated our FLAME trial to prospectively study FlowTriever for massive PE patients, and announced the PEERLESS randomized controlled trial for intermediate risk PE patients. We introduced seven new products, obtained an important new clinical indication to expand our TAM, and successfully launched all of our devices in Europe. While it has not been our goal, we've accomplished all of this while maintaining positive cash flows from our operations. We believe all of this suggests that our technology has tremendous impact on patients. Our value proposition resonates broadly and consistently, and our team executes regardless of external circumstances. We remain focused on building our company for the long haul, and we believe we can and will continue to execute effectively and grow aggressively. I'd now like to share with you more specific and recent progress we continue to make on all five of our growth drivers. Our first growth driver is the expansion of our sales organization to target new hospitals and physicians. The size of our core TAM is large, as you know, and despite our continued growth, we believe that only about 6% of all patients in the U.S. who can and probably should benefit from our procedures were actually treated in Q3. Our efforts to penetrate this market will require a lot more sales professionals. Earlier this year, we shared with you that we are targeting 180 to 200 territories by the end of the year. We remain on track to comfortably land in the high end of this range. Our second growth driver is building awareness and driving deeper adoption at existing hospital customers. As you know, a high percentage of our target PE and DVT patient populations are currently treated with anticoagulation alone. Education and training of the non-interventional physicians who are often responsible for treatment decisions for these patients is important, and we continue to engage these physicians effectively. We are also working with administrators to establish systematic processes to identify and triage VTE patients consistently to the VTE experts. The goal is to establish systems like those adopted for stroke and heart attack patients. Altogether, these efforts, which we have designated our VTE Excellence Program, are yielding encouraging results. More centers, for example, are establishing VTE coordinator positions every quarter, and penetration rates at targeted centers are climbing. We look forward to providing updates as we continue to execute the program. Our third growth driver is to build upon our base of clinical evidence. We again have a lot to share on this topic. Data from the first 500 patients enrolled into our FLASH registry were presented at the TCT conference last week. This study already represents the largest ever prospective interventional data set in the field of PE. The data confirm the best-in-class safety profile of FlowTriever system, impressive on-table clinical improvement, while the median ICU stay remains 0 days. Perhaps more exciting, as we are now reporting patient data out to six months, we believe that treatment with FlowTriever fundamentally changes the natural course of this disease. All-cause mortality at all points of follow-up, as well as the rates of CTEPH and CTED, which represent the terrible long-term consequences for survivors of this disease, are orders of magnitude better than those reported in the literature for PE patients treated with conservative medical management. In a separate study recently published in a high-impact peer-reviewed journal, Dr. Buckley and colleagues reported the first-ever comparison of PE patients treated with a thrombectomy device, the FlowTriever, to patients treated with anticoagulation and lytics. The results are impressive. Patients treated with FlowTriever showed an 85% reduction in in-hospital mortality and a four day reduction in ICU stay. Finally, we are pleased to report that our PEERLESS randomized controlled trial comparing FlowTriever to catheter-directed thrombolysis remains on schedule. The protocol is complete. Site selection is underway, and we expect first patient enrollment in Q1 of 2022. Our fourth growth driver is to expand our product portfolio. Exciting developments here as well. First, FlowSaver has lived up to expectations. As a reminder, FlowSaver is a device used to simply return blood aspirated during a FlowTriever procedure to the patient, allowing virtually bloodless thrombectomy. This is important because it enables the physician to whoosh as many times as necessary without concern for blood loss. Estimated blood loss per procedure, in fact, is down by 80%, even as the number of washes per procedure has increased by 33%. Adoption has been brisk. FlowSaver has already been used in nearly 2,500 procedures. Bloodless thrombectomy is highly valuable for physicians and patients, and it sets a high performance bar for both existing and future competitors. Next, we received FDA clearance for the ClotTriever BOLD in October. The BOLD is a more aggressive ClotTriever system, which may allow us to treat older clots and more advanced DVT. In fact, it represents the first in a suite of products we will bring to market over time to treat patients with post-thrombotic syndrome or PTS. PTS is a horrendous progressive condition that develops in about half of all untreated DVT patients and often results in venous leg ulcers. There are at least 1 million patients in the United States right now with venous leg ulcers, and PTS is the cause of about 60% of them. We'll have more to say about ClotTriever BOLD, along with the remainder of our robust product pipeline over the coming quarters. Our fifth and final growth driver is expansion into adjacent and international markets. The operating environment has stabilized across Europe and we continue to make progress on launching this business. We have successfully established a commercial presence across all major European markets through a combination of direct teams and third-party distribution partnerships. Enthusiasm and feedback from physicians remain highly positive and we are seeing steady increases in our monthly case volumes. In addition to supporting and driving initial cases, we are also gaining clarity and executing on longer term clinical and reimbursement strategies we will need to help build out our European franchise. Beyond Europe, we're making progress on regulatory paths in both Japan and China, although the approval timelines remain years away. We remain very optimistic about the longer-term potential for our international business, but we believe it will not materially contribute in the immediate term. Finally, I appreciate always the opportunity to close by reminding you that our work here is more important to us than just business. We are committed to a mission. We appreciate you believing along with us in extraordinary possibilities, and we appreciate your continued support. We are just getting started. We believe we can and will grow sustainably and aggressively for many years to come. With that, I'd like to turn things over to Mitch. Thank you, Bill, and good afternoon, everyone. Inari revenues for the third quarter of 2021 were $72.9 million, compared to $63.5 million for the prior quarter and up $34.2 million or 88% from $38.7 million for the same period of the prior year. Compared to Q3 of 2020, we have expanded our sales force, opened new accounts, and achieved deeper penetration of our products into existing accounts. Revenue was split between our two products as follows. 30% of our revenue was derived from the sale of ClotTriever products during the third quarter of 2021, compared with 37% in the third quarter of 2020. Seventy percent was derived from the sale of FlowTriever during the third quarter of 2021, compared to 63% in the same period of the prior year. During Q3, the vast majority of our revenues came from procedures. Our stocking revenue was consistent with the level we saw during Q2 of 2021 due to the broad acceptance of several of our new products, including the FlowSaver, which we introduced in Q3 of 2021. We expect our stocking revenue as a percent of total revenue will moderate over time. Gross margin was 90.3% for the third quarter of 2021, compared with 91.7% in the third quarter of 2020. A 140 basis point decline was due primarily to a change in inventory management in anticipation of our facility move. Operating expenses were $68.6 million in the third quarter of 2021, compared with $28.3 million for the same period of the prior year. R&D expense was $12.5 million in the third quarter, compared with $5.2 million in the same period of 2020. The $7.3 million increase in R&D expense was primarily driven by an increase in headcount as well as product development and clinical evidence development costs. SG&A expense was $56.1 million in the third quarter of 2021, compared with $23.1 million for the same period of the prior year. The $33 million increase was primarily due to personnel-related expenses as a result of increased headcount across our organization, travel expenses, and sales and marketing costs. As a reminder, Q3's SG&A expense, net loss, and net loss per share include the impact of an $8.3 million one-time non-cash stock-based comp charge. Net loss for the third quarter of 2021 was $2.8 million, compared with net income of $6.5 million for the same period of the prior year. The basic net loss per share for the third quarter of 2021 was $0.06 based on the weighted average basic share count of 50 million. The fully diluted share count as of the end of Q3 was $55.5 million. This compares with a basic and fully diluted net income per share of $0.13 and $0.12, respectively, and a weighted average basic and diluted share count of $48.3 million and $55.4 million, respectively, for the same period of the prior year. I'd like to move on to a few balance sheet updates. Our cash of $81.2 million and investments of $87.4 million at the end of Q3 2021 totaled $168.6 million compared to $164.2 million at the end of the fourth quarter of 2020. We have not yet utilized our $30 million revolving credit facility, although we ended the third quarter with borrowing capacity under the credit line of approximately $28.2 million. Our cash flows used in operating activities were $5.6 million in Q3 of 2021 compared to cash generated by operating activities of $7.3 million in Q2 of 2021. On a sequential comparison basis, our cash used during Q3 relates primarily to investments in our new production and office facility. I'll close my comments by addressing Inari's financial guidance. We are comfortable increasing our full year revenue guidance to $266 million to $268 million, up from our previous guidance of $250 million to $255 million. With that, I'd like to turn the call back to the moderator for questions. Thank you. To ask a question, you will need to press Star then One on your telephone. To withdraw your question, please press the Pound key. Please stand by while we compile the Q and A roster. Our first question comes from the line of Cecilia Furlong with Morgan Stanley. Your line is now open. Great. Thank you for taking the questions. Bill, I wanted to start with FlowSaver and just see if you could provide a bit more commentary around what you've seen from an adoption standpoint to date, just in terms of procedures utilizing it, and then as you look forward as well, just the ability for FlowSaver to expand your user base and bring physicians off the sidelines who are reticent to use FlowTriever due to concerns around blood loss. Yeah. Thanks, Cecilia, good to talk with you. Just as a quick aside here, we have joining me for questions and answers, maybe even this question, our Chief Operating Officer, Drew Hykes, and Dr. Tom Tu, who is our Chief Medical Officer. Thanks for the question. First of all, the adoption has been brisk as we communicated in the prepared remarks. It is in the hospitals that already have FlowSaver, the percentage is very high. I would say almost all cases in almost all centers that have FlowSaver, if they're doing more than one whoosh, they're probably using FlowSaver. It is very high rates of adoption. The centers that don't have FlowSaver on the books in the hospital just yet, that is a function mostly of, you know, the administrative challenges of going through value analysis committees and so forth. Because it's part of the per procedure pricing, there's not an additional cost. These are purely administrative hurdles, and we'll get through them. We do actually believe already that we've seen some people pick up FlowTriever because the risk is lower, right? The potential for multiple whooshes with a much lower consequence for, you know, just missing is lower. There's essentially no consequence for that. Yes, we actually believe that this is not only exciting for our current user base, but that it is a driver of adoption. Okay, great. I wanted to ask too, just on your comments around the OUS expansion, what you've seen in the quarter, but if you could talk a bit more about just your outlook today around both the clinical and reimbursement work needed to really open up some of those markets, especially in Europe over the next several years? Thank you. Yeah, Cecilia, it's Drew Hykes. I can get started on that one. Not a whole lot to add beyond what you heard, Bill describe in the prepared remarks. We like what we're seeing so far in Europe. Lots of positive momentum. We've done cases now across most of the major European markets. We're doing cases every day now, essentially. The monthly trends are positive, incremental growth month after month, and lots of enthusiastic feedback from the physician community. We are getting more clarity on the reimbursement and clinical work that we're going to need to do, market by market, to really put ourselves in a position to drive broad adoption of both technologies. In some cases, that will look like dedicated clinical studies we'll need to do in some of those markets, to submit that evidence to the reimbursement, authorities and gain broad-based reimbursement. Those strategies are coming into view. In some of those markets, that's gonna take us a number of quarters to complete that work. In the meantime, we are gonna be able to access and continue to access, opportunistically, more account level and regional level budgets, which will allow us to continue to do cases and expand the franchise even as we, undertake that longer term reimbursement clinical work that I described. Having said all that, we still view this as a longer term growth driver for us, and wouldn't anticipate the international business being a material contributor to the overall commercial franchise, you know, really for the foreseeable future. We'll continue to keep you posted on the progress, but for now, we like what we're seeing. Great. Thank you for taking the questions. Thank you. Our next question comes from the line of Larry Biegelsen with Wells Fargo. Your line is now open. Hey guys, congrats on a nice quarter here. Thanks for taking the questions. I just wanted to start, you guys obviously had a great quarter, but I'm trying to understand the bridge from Q3 to Q4 implied in the guidance. So, you know, maybe talk about stocking a little bit. We estimated about $12.5 million in Q3. Is that close? And how should we think about, you know, what's implied in Q4? And Mitch, I heard your comments on it moderating over time, but just comments on 2022 stocking. Sure. would be helpful. Just lastly, the COVID assumption for Q4, just the pieces, the moving parts and stocking and COVID and anything else we should understand on kind of the, it's, you know, the implied 1% sequential growth in Q4. Thanks. Sure. Not a problem, Larry. The stocking figure you quoted is really pretty much right. Kind of that $12.5 million range. I think that's something that we see as being pretty consistent with where we were in Q2 on a percentage basis. percent of total revenue that, you know, speaks to the really strong acceptance that we've had in the marketplace, you know, from the T24 and the T20 catheter and the FT2 and some other, the FlowSaver obviously, which we just talked about with Cecilia. From a 2022 point of view, I made the comment about moderation in stocking revenue. I think, you know, moderation is sort of a term of art, obviously. We are very excited about the product announcement. More sort of a menu for 2022. We'll get into that, you know, obviously in a lot more detail as we turn the page on the new year. We believe we'll continue to have some strong acceptance by our customers of these new products that does generate some one-time technical upgrade revenue. I think as the number of accounts grows and basically the base of procedural revenue grows in the business, the stocking revenue will inevitably fall as a percent of total. I hope that helps a little bit. You know, in terms of our- It does. Q4 guidance, I think you're kind of also focusing and asking about that a little bit, and maybe I can get this started, you know, Bill and Drew can jump in and help with it, but we're very, you know, pleased with where we are in terms of thinking about Q4. You know, obviously to be able to raise by a significantly greater amount than we beat, that's a nice thing. We think that, you know, stocking could play a part in Q4 in terms of potentially a little bit of a headwind, you know, as well as the reduction in COVID procedures and things of that kind, the hospital staffing shortages. There's three or four factors that kind of go into our thinking about that. You know, we of course don't wanna get ahead of ourselves in terms of our guidance, and we felt comfortable that that's a good number and hopefully one that'll be helpful to you and others in terms of thinking about the business short term. You know, the more important thing I think is just the long-term potential for the business, and we're frankly more excited than ever. You know, we probably treated still about 6% of the patients in Q3 who could have been helped with the use of our various products, and there's so much opportunity there for us in the future that we couldn't be more excited about that and to be a part of it. Yeah. I guess the only thing I'd add there, Larry- Yeah, please. Go ahead. The only other thing I'd add, Larry, is, you know, we are I guess as frustrated as anybody with the waxing and the waning of the pandemic and the COVID surges and the challenges that creates. You know, we're facing exactly the same sets of headwinds that everyone else faces with regard to, you know, staff shortages, limitations, hospital resources, you know, procedure volumes are down in many hospitals, whole cath labs taken out. I mean, all those challenges. Yet, we have been able to grow, right? Even if you eliminate completely, if COVID did not cause VTE and we didn't see any sort of, you know, upside on those sorts of patients, I think we'd be very pleased with 8% growth sequentially from Q2 to Q3, especially given all these challenges that everyone's facing. You know, at some point here, we think the operating environment is gonna return to some sort of normalcy, and we think we can do even better right when we have, you know, full bandwidth and access. Right now, I think what you're seeing with the COVID Q4 implied guidance is just we just wanna make sure that we never, ever overpromise. We want to acknowledge also the, you know, uncertainties that remain out there, while at the same time, acknowledging the fact that we do continue to execute in the penetration of our core TAM very effectively. That's very helpful. Thanks, Bill. You know, I mean, obviously you guys in September, you know, talked about transforming the company. I can't remember exactly what you said, but I'm pretty sure you used the word, you know, transform, which is obviously, you know, something we don't hear every day from a CEO. So I guess my question, my questions are, you know, how are you thinking about in-adjacencies? You know, is this organic versus inorganic? And, you know, when are we gonna learn more? And do you have an analyst meeting or investor meeting set for 2022? And I might try to slip one more in if you let me. So go ahead. Well, you're already at seven or eight, Larry. I know. It's okay. We get it completely. I'll see if I can get all these in. You remind me, since I have ADD, you'll have to remind me, if I miss them. I think you're starting to see now a cadence of products. There's a bit of a track record now. I think we've talked about seven ahead of this call, seven new products. This one, the ClotTriever BOLD, is the first in what we believe a series of products. This is a really challenging disease state. Clot. It's really not clot, it's scar tissue, and eventually it causes post-thrombotic syndrome. I think you'll see us working on that market, just communicating a bit more in terms of numbers of patients. Very large market. Our ability to address that market over time. Again, it's a challenging disease state, so we'll see. That's the first. We believe there are several other new products that are coming down the line here. You've been very, all of you have been very patient with us. We don't wanna break any new news here, but again, these things are beginning to materialize now as you're seeing with ClotTriever BOLD. There'll be a number of other adjacencies that we enter. We're not going to talk at all about inorganic opportunities, pro, con, when. You know, we're just not gonna comment on those things for, you know, for obvious reasons. Did I miss any questions there, Larry? Is there another one? Analyst meeting for next year. Analyst meeting. We're not quite ready to communicate a date, but I think we've shared publicly that we do plan at some point in the probably first half of the year to do an analyst meeting. We're working on dates now, and we'll have some things to say about that shortly. Just lastly on BOLD, I just wanted to follow up. What is the status of the launch? You know, how are these patients treated today? You know, what makes BOLD, you know, appropriate for them? Thanks for taking the questions. Yeah. Larry, it's Drew. I can get started on that one. We are in the early phases of what we call the LMR, the limited market release for BOLD. We got clearance here just at the end of October, so we're still in the early days. We've done, I don't know, a dozen or so cases. Still very early in understanding how that product performs in some of these longer term patients that have these PTS-related ulcers and the longer term kind of scar as opposed to clot. Those patients today don't have great treatment options. That's why there's such a dramatic unmet need for that particular patient population. They suffer from severe PTS. Many of them have ulcers and wounds that are unhealed. Their quality of life is atrocious, and they get kinda passed around the system without anyone being able to offer definitive treatment. That's exactly the unmet need that we've identified and what we hope we're gonna be able to address over time. ClotTriever BOLD, as you heard Bill describe, is really the first of what we envision as a system to try and help those patients. Still early days. We're just getting started on the LMR, and we'll keep everyone posted as we learn more about how that product is performing out in the market in these patients. Thanks, Drew. Thanks for taking all the questions, guys. Our pleasure. Thanks, Larry. Our next question comes from the line of Bill Plovanic with Canaccord. Your line is now open. Hi, it's Sean for Bill tonight. Thanks for taking our questions. First, I just wanted to ask, have you had any discussions regarding CMS removing the NCD for Transvenous Catheter Pulmonary Embolectomy or any subsequent discussions with payers or administrators since that decision? Yeah. This is Drew again. I can give you some quick updates on the NCD. Good news there. About two weeks ago, CMS announced publicly that they were removing that NCD effective immediately. That NCD 240.6 no longer exists. It was never a particular overhang for our business. More of a distraction really over the last couple years. Nonetheless, we were pleased to see CMS respond to numerous physician societies and dozens and dozens of individual physicians that had all advocated for removing that NCD that stretched back to 1983. We have proactively reached out to a handful of the private commercial payers that had reference to that NCD within their systems and updated them that it has now been removed. All that has taken place over the last couple weeks. Again, it was not necessarily at all a headwind or an overhang for the business, so we haven't seen any impact commercially other than clearing up that distraction and avoiding having to spend any time or additional bandwidth describing it or talking about it. Great. Thanks for that color. Can you also just talk about the runway for continued penetration in existing accounts and perhaps how many accounts today are only using FlowTriever or only using ClotTriever? Thanks. We're in about 1,200 accounts active here in Q3. We added a similar number of new accounts that you've seen us add on a quarterly basis. That 1,200 accounts, over 60%, almost two-thirds actually, are using both technologies, which obviously means there's 30-some% that are using only FlowTriever or only ClotTriever. It's really a mix, a pretty balanced mix at those single technology accounts. That's the status as of Q4. We continue to make progress on pulling in, you know, those second technologies into the accounts where we have that opportunity. The vast majority of our case volume is coming from existing accounts, from driving deeper penetration. Over 90% of our cases in the quarter came from those existing accounts. That second growth driver that we talk about, I think, is increasingly important to driving the growth, and that's exactly what we saw here in Q3. Great. If I could just sneak in one more for you, Drew, too, probably. Just the field force size exiting the quarter? Yeah, I think we communicated in the prepared remarks that the previously projected 180 to 200 territories by the end of the year and that we were on pace to you know kind of finish in the high end of that range. I think we'll leave it there without any. Hopefully it's okay to leave it there without any further detail. We've had no you know it's always a challenge to hire and train and onboard, but we've had no you know COVID related additional challenges. We've been very crisp with the execution of our you know hiring, training and onboarding program. Great. Thank you for taking our questions. Thanks, Sean. Thanks, Sean. Thank you. Our next question comes from the line of Marie Thibault with BTIG. Your line is now open. Hi. Hi, Inari team. Congrats on a strong quarter and thanks for taking my questions tonight. I wanted to start here, I guess with a follow-up on Bold and just try to clarify, you know, reading a little bit about the design of the catheter. I'm curious whether post-thrombotic syndrome is included in the label, and if so, what clinical data was sort of introduced there to win that? Yeah. We can, you wanna start with the- Sure. the labeling to, Drew? Yeah. That product, the design is really very similar in a lot of ways to the existing ClotTriever system. The initial labeled indication here out of the gate mirrors what we have in place for the ClotTriever, kind of the core ClotTriever product itself. No big changes there. Over time, again, as we get more experience with the product and understand how it's performing, we may decide to undertake some additional work to expand that labeling and update that labeling, but that's the status as of where we are today. Marie, it's Tom here. Okay. I thought I might provide a little clinical background about post-thrombotic syndrome. You can imagine patients who are undertreated for deep venous thrombosis may end up having scar tissue and occlusion of their veins due to poor healing. These patients really have no options. They're the ones with swelling in their legs chronically, non-healing venous ulcers. The ability to modify the tissue, remove tissue, open up channels, reduce the venous pressure has resulted in healing of these venous leg ulcers in patients that we've already treated. We're really excited to explore this new market of patients that we hope to benefit, but I think we're quite early on in this experience. Okay. That's great to hear. I appreciate that color. Then if I could ask here on staffing shortages. We've been hearing across this quarter from several med tech peers that staffing shortages have led to kind of constraints on procedures. I'm curious what the impact was, if any, on Inari this quarter? Yeah. Thanks, Marie. I think the answer is it's really hard to measure. We hear anecdotally, for example, that, you know, this hospital or that had to close down one of their labs or a couple of their labs, or they have to close early and they're trying to manage procedure volumes in the cath lab, you know, pulling nurses from one place or another, you know, hiring traveling nurses. There's any number of anecdotal challenges, and I suspect you've heard this from our other, from some of our peers. The fact is, however, even in our core TAM, we continue to grow, you know, pretty robustly. I think the key here is that some procedures are getting done, right? I think our procedures carry a profile and our patient population carries a profile that is, you know, kind of a little bit higher in the priority. A lot of our patients, especially the PE and pretty significant percentage of the DVT patients, are considered emergent. That's one part of this. The second part, of course, is that our procedures are fast and easy to perform and require limited hospital resource. There's no ICU status required. We believe pretty strongly in a lot of our hospitals, their own metrics suggest these patients leave the hospital a little bit more quickly. I hinted at that with the patient story that I shared a little earlier as well. These are the sorts of procedures that are getting done based on characteristics of the patient, high acuity setting, emergency, emergent type setting, and the characteristics of the procedure just requiring limited resource. I think, secondary to all of that, but important for hospitals that continue to be, you know, kind of financially burdened by the pandemic, these nobody's losing money on these procedures, and I think that's an important component. That makes sense. Okay. Makes a lot of sense. One last quick housekeeping one, if I can sneak it in. I heard the 6,700 total procedures or so this quarter. Do you have the split between DVT and PE procedures? Yeah. The split, and I think this is also in the queue. From a revenue point of view, the split was 70/30, which I talked about. Yep. Yep. Yep. The case for the quarter was 51% DVT and 49% PE. Perfect. Thank you so much. The difference is the weighting toward, as always, PE in terms of revenue is- Mm-hmm. primarily based on average selling prices being a little higher in PE as well as PE devices. The FlowTriever is often used in DVT procedures and is often in combination with ClotTriever. That's why it represents a little bit higher percentage of revenue than procedures. Perfect. I appreciate the time tonight. Thanks, Marie. Thanks, Marie. Thank you. Our last question comes from the line of Danielle Antalffy with SVB Leerink. Your line is now open. Hi, guys. This is Priya on for Danielle. Congrats on a great quarter, and thanks for taking the questions. I have one kind of a follow-up from the last one. You know, just I understand that there's a higher mix for FlowTriever in the quarter kind of related to, you know, ASP. But, you know, are you guys seeing anything within the quarter and within the market that's from like a competitive dynamic or even COVID-related that's raising a higher awareness around PE? Another follow-up for me. You wanna take the awareness, Tom? Sure. You know, we've talked a lot about COVID influencing the incidence of disease as well as perhaps being a headwind in many systematic ways. One thing is certain that COVID has done nothing but increase awareness about blood clots in general. I would not say that there's a predilection for pulmonary embolism over DVT in terms of the awareness issue. I think both of these are diseases associated with COVID and are now part of the common parlance. Great. Thank you for that. Just another one for me here. It looks like procedures increased about mid-single digits quarter-over-quarter, ex COVID impact. Is that the right way to think about it, about the underlying growth, or is there any seasonality factor, in here? Yeah. I think you heard Bill describe in the prepared remarks that the procedure growth in our core TAM was 8%, so even higher than the number you quoted. We like what we saw. We continue to execute, we think, crisply, across the board, and you're seeing that reflected in the core TAM. You know, all of those growth drivers that we discuss remain intact, and we continue to make good progress across the board on each of them. I think taken together, that's what's contributing to the kind of growth that we're able to demonstrate in Q3, and I think gives us some confidence heading into the end of the year. Great. Thank you. Thanks, Priya. Thanks, Priya. There are no further questions at this time. Very good. Thank you. Thanks, everyone. Thanks for joining us.